Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Advagraf pre-transplant pharmacokinetics in de novo kidney transplant recipients
2013-000985-13Phase 4Terminated
- Sponsor
- Astellas Pharma
- Start
- Oct 2013
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tacrolimus in kidney allograft rejection, sponsored by Astellas Pharma. Primary endpoint: Dose of tacrolimus required to achieve target trough concentration on Day 3. Started Oct 2013; status: terminated.
02
Drugs
tacrolimus
03
Conditions
kidney allograft rejection
Beyond the preview
Go deeper on 2013-000985-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000985-13.